CL2011000594A1 - Combinacion farmaceutica que comprende: a) 10-45% de alisquireno, b) 0,5-5% de amlodipina, c) 2-15% de un desintegrante, d) 1-60% de un diluyente, e) 0,1-20% de un aglutinante, f) 0,1-5% de un lubricante, g) 0,05-5% de un derrapante y h) opcionalmente un relleno; metodo de preparacion; uso para tratar hipertension. - Google Patents

Combinacion farmaceutica que comprende: a) 10-45% de alisquireno, b) 0,5-5% de amlodipina, c) 2-15% de un desintegrante, d) 1-60% de un diluyente, e) 0,1-20% de un aglutinante, f) 0,1-5% de un lubricante, g) 0,05-5% de un derrapante y h) opcionalmente un relleno; metodo de preparacion; uso para tratar hipertension.

Info

Publication number
CL2011000594A1
CL2011000594A1 CL2011000594A CL2011000594A CL2011000594A1 CL 2011000594 A1 CL2011000594 A1 CL 2011000594A1 CL 2011000594 A CL2011000594 A CL 2011000594A CL 2011000594 A CL2011000594 A CL 2011000594A CL 2011000594 A1 CL2011000594 A1 CL 2011000594A1
Authority
CL
Chile
Prior art keywords
alisquirene
amlodipine
pharmaceutical combination
disintegrant
preparation
Prior art date
Application number
CL2011000594A
Other languages
English (en)
Spanish (es)
Inventor
Robert Frank Wagner
Spephen Valazza
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011000594A1 publication Critical patent/CL2011000594A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011000594A 2008-09-22 2011-03-21 Combinacion farmaceutica que comprende: a) 10-45% de alisquireno, b) 0,5-5% de amlodipina, c) 2-15% de un desintegrante, d) 1-60% de un diluyente, e) 0,1-20% de un aglutinante, f) 0,1-5% de un lubricante, g) 0,05-5% de un derrapante y h) opcionalmente un relleno; metodo de preparacion; uso para tratar hipertension. CL2011000594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22

Publications (1)

Publication Number Publication Date
CL2011000594A1 true CL2011000594A1 (es) 2011-08-05

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000594A CL2011000594A1 (es) 2008-09-22 2011-03-21 Combinacion farmaceutica que comprende: a) 10-45% de alisquireno, b) 0,5-5% de amlodipina, c) 2-15% de un desintegrante, d) 1-60% de un diluyente, e) 0,1-20% de un aglutinante, f) 0,1-5% de un lubricante, g) 0,05-5% de un derrapante y h) opcionalmente un relleno; metodo de preparacion; uso para tratar hipertension.

Country Status (21)

Country Link
US (1) US8613949B2 (enExample)
EP (1) EP2328564A2 (enExample)
JP (2) JP2012503020A (enExample)
KR (1) KR20110060942A (enExample)
CN (1) CN102159195A (enExample)
AR (1) AR073384A1 (enExample)
AU (1) AU2009292908B2 (enExample)
BR (1) BRPI0919350A2 (enExample)
CA (1) CA2736257A1 (enExample)
CL (1) CL2011000594A1 (enExample)
CO (1) CO6351711A2 (enExample)
EC (1) ECSP11010999A (enExample)
IL (1) IL211571A0 (enExample)
JO (1) JO3239B1 (enExample)
MA (1) MA32719B1 (enExample)
MX (1) MX2011002988A (enExample)
MY (1) MY153610A (enExample)
PE (1) PE20110293A1 (enExample)
RU (2) RU2011115712A (enExample)
TW (1) TW201016217A (enExample)
WO (1) WO2010033954A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (en) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
RU2426532C2 (ru) * 2004-03-17 2011-08-20 Новартис Аг Применение органических соединений
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
WO2006059217A1 (en) 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20120542A1 (es) * 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US8119841B2 (en) * 2006-11-07 2012-02-21 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
JP2015091830A (ja) 2015-05-14
RU2014140552A (ru) 2015-06-20
TW201016217A (en) 2010-05-01
IL211571A0 (en) 2011-05-31
RU2011115712A (ru) 2012-10-27
WO2010033954A2 (en) 2010-03-25
US20110165240A1 (en) 2011-07-07
BRPI0919350A2 (pt) 2015-12-29
US8613949B2 (en) 2013-12-24
JO3239B1 (ar) 2018-03-08
JP2012503020A (ja) 2012-02-02
CO6351711A2 (es) 2011-12-20
CN102159195A (zh) 2011-08-17
AU2009292908A1 (en) 2010-03-25
WO2010033954A3 (en) 2010-10-21
MY153610A (en) 2015-02-27
MX2011002988A (es) 2011-04-11
AU2009292908B2 (en) 2012-07-26
CA2736257A1 (en) 2010-03-25
EP2328564A2 (en) 2011-06-08
MA32719B1 (fr) 2011-10-02
AR073384A1 (es) 2010-11-03
ECSP11010999A (es) 2011-06-30
KR20110060942A (ko) 2011-06-08
PE20110293A1 (es) 2011-05-17

Similar Documents

Publication Publication Date Title
CL2013001600A1 (es) Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
WO2010044981A3 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CL2008003848A1 (es) Compuestos derivados de fenilo o heteroarilo bis-sulfonilamino sustituidos, inhibidores de prostaglandina e sintasa-1 microsomal; composicion farmaceutica; procedimiento de preparacion; procedimiento de preparacion de la composicion farmaceutica; y uso en el tratamiento del dolor agudo o cronico, dolor nociceptivo o dolor neuropatico.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
NO20092609L (no) Tannate salt of rasagiline
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
MA32797B1 (fr) Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
EA201070256A1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
EA201100756A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
NO20082298L (no) Kaliumkanalinhibitorer
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
CL2011001078A1 (es) Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras.
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme